Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Transplant Proc. Author manuscript; available in PMC 2010 October 19.
Published in final edited form as:
Transplant Proc. 1992 June; 24(3): 985.
PMCID: PMC2957115

Long-Term Survival of Donor-Specific Pancreatic Islet Xenografts in Fully Xenogeneic Chimeras

The development of procedures to isolate large numbers of purified human pancreatic islet cells has made it possible to initiate a new phase of clinical trials in pancreatic islet transplantation for treatment of type I diabetes.14 Although nonspecific immunosuppressive agents have been instrumental in controlling alloreactivity to transplanted islet cells, rejection still occurs and is a major limitation to islet transplantation.5,6 The induction of donor-specific transplantation across a species barrier, using bone marrow stem cells to produce chimerism and induce donor-specific transplantation tolerance, has been suggested as a potential approach to prevent rejection of transplanted cells.79 The purpose of this study was to determine whether long-term acceptance and function of xenogeneic pancreatic islet grafts could be achieved in fully xenogeneic chimeras.


Fully xenogeneic chimeras were prepared by transplantation of 40 × 106 non-TCD Wistar Furth bone marrow cells into C57BL/10 Sn mouse recipients conditioned with 950 R rads total body irradiation before transplantation. Animals were typed for chimerism at 4 weeks and made diabetic by intravenous injection of streptozotocin (165 mg/kg). Only mice with a plasma glucose concentration exceeding 300 mg/dL for 1 week were used as islet recipients. Rat pancreatic islets were obtained by the modification of an automated method for isolation of human pancreatic islet cells and purified by the COBE cell separator with Euro-Collins-Ficoll gradients.4 Eight hundred donor-specific Wistar Furth or third-party F344 rat pancreatic islets were implanted beneath renal capsule of diabetic chimeras. Nonfasting blood glucose levels were determined daily to check function.


The survival of the donor-specific Wistar Furth rat pancreatic islet xenografts was significantly prolonged (mean survival time > 120 days), while major histocompatability complex disparate third-party F344 islets were rapidly rejected (mean survival time = 8 days). The donor-specific grafts were functional and maintained the normoglycemic state in chimeras. This study demonstrated that long-term survival and function of donor-specific pancreatic islet xenografts can be obtained in fully xenogeneic chimeras.


Supported in part by Juvenile Diabetes Foundation Research Grant no. 1911433.


1. Warnock GL, Kneteman NM, Ryan E, et al. Diabetologia. 1991;34:55. [PubMed]
2. Scharp DW, Lacy PE, Santiago JV, et al. Transplantation. 1991;51:76. [PubMed]
3. Tzakis QAG, Ricordi C, Alejandro R, et al. Lancet. 1990;18:402. [PMC free article] [PubMed]
4. Scharp DW, Lacy PE, Santiago JC, et al. Diabetes. 1990;35:515. [PubMed]
5. Kahan B, Van Buren C, Bioleau M. Transplantation. 1983;35:9.
6. Starzl TE, Todo S, Fung JJ, et al. Transplant Proc. 1990;22:3.
7. Ildstad ST, Sachs DH. Nature. 1984;307:170. [PubMed]
8. Hartner WC, Defazio SR, Maki T, et al. Transplantation. 1986;42:593. [PubMed]
9. Ildstad ST, Wren SM, Boggs SS, et al. J Exp Med. (in press) [PMC free article] [PubMed]